• IRadimed Corp IRMD.OQ IRMD.O is expected to show a rise in quarterly revenue when it reports results on April 30 (estimated) for the period ending March 31 2025

• The Winter Springs Florida-based company is expected to report a 9.9% increase in revenue to $19.332 million from $17.6 million a year ago, according to the mean estimate from 2 analysts, based on LSEG data.The company's guidance on February 13 2025, for the period ended March 31, was for revenue between $19.20 million and $19.40 million.

• ​LSEG's mean analyst estimate for IRadimed Corp is for earnings of 41 cents per share. The company's EPS guidance on February 13 2025, for the period ended March 31, was between $0.39 and $0.43

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The mean earnings estimate of analysts was unchanged in the last three months. ​

• Wall Street's median 12-month price target for IRadimed Corp is $71.00​, above​ its last closing price of $53.32. ​​​

This summary was machine generated April 28 at 13:19 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)